These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17441475)

  • 1. [NKT cell-mediated immunotherapy for hematological malignancies].
    Fujii S
    Rinsho Ketsueki; 2007 Mar; 48(3):188-99. PubMed ID: 17441475
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer Immunotherapy by coordinated stimulation of innate lymphocytes (NK and NKT cells).
    Fujii S
    Rinsho Ketsueki; 2009 May; 50(5):364-74. PubMed ID: 19483396
    [No Abstract]   [Full Text] [Related]  

  • 3. NK cells: innate immunity against hematological malignancies?
    Costello RT; Fauriat C; Sivori S; Marcenaro E; Olive D
    Trends Immunol; 2004 Jun; 25(6):328-33. PubMed ID: 15145323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors.
    Rey J; Veuillen C; Vey N; Bouabdallah R; Olive D
    Trends Mol Med; 2009 Jun; 15(6):275-84. PubMed ID: 19487160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cellular immunotherapy for hematological malignancies].
    Yasukawa M
    Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
    [No Abstract]   [Full Text] [Related]  

  • 6. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
    Fujii S
    Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells in innate immunity and cancer.
    Becknell B; Caligiuri MA
    J Immunother; 2008 Oct; 31(8):685-92. PubMed ID: 18779751
    [No Abstract]   [Full Text] [Related]  

  • 8. Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection.
    Vasan S; Poles MA; Horowitz A; Siladji EE; Markowitz M; Tsuji M
    Int Immunol; 2007 Aug; 19(8):943-51. PubMed ID: 17702988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell modulation in immunotherapy for hematological malignancies.
    Lin C; Chen S; Li Y
    Cell Biol Toxicol; 2017 Aug; 33(4):323-327. PubMed ID: 28474249
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular profiling reveals distinct functional attributes of CD1d-restricted natural killer (NK) T cell subsets.
    Rolf J; Berntman E; Stenström M; Smith EM; Månsson R; Stenstad H; Yamagata T; Agace W; Sigvardsson M; Cardell SL
    Mol Immunol; 2008 May; 45(9):2607-20. PubMed ID: 18304639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible application of natural killer cells and interleukin-2 in therapy of human leukemia.
    Lotzová E
    Prog Clin Biol Res; 1987; 244():259-66. PubMed ID: 3498951
    [No Abstract]   [Full Text] [Related]  

  • 12. IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances.
    Shanmugham LN; Petrarca C; Frydas S; Donelan J; Castellani ML; Boucher W; Madhappan B; Tete' S; Falasca K; Conti P; Vecchiet J
    J Exp Clin Cancer Res; 2006 Dec; 25(4):529-36. PubMed ID: 17310844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Working with NKT cells--pitfalls and practicalities.
    Berzins SP; Smyth MJ; Godfrey DI
    Curr Opin Immunol; 2005 Aug; 17(4):448-54. PubMed ID: 15963710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functionally distinct NKT cell subsets and subtypes.
    Seino K; Taniguchi M
    J Exp Med; 2005 Dec; 202(12):1623-6. PubMed ID: 16365145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of type 1 diabetes by NKT cells.
    Novak J; Griseri T; Beaudoin L; Lehuen A
    Int Rev Immunol; 2007; 26(1-2):49-72. PubMed ID: 17454264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms].
    Oka Y; Tsuboi A; Nishida S; Hosen N; Nakata J; Hashii Y; Maeda T; Oji Y; Kumanogoh A; Sugiyama H
    Rinsho Ketsueki; 2011 May; 52(5):235-42. PubMed ID: 21646768
    [No Abstract]   [Full Text] [Related]  

  • 18. T-cell therapy after hematopoietic stem cell transplantation.
    Kennedy-Nasser AA; Brenner MK
    Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Killer dendritic cells and their potential role in immunotherapy.
    Ullrich E; Chaput N; Zitvogel L
    Horm Metab Res; 2008 Feb; 40(2):75-81. PubMed ID: 18283624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells.
    Naoe M; Ogawa Y; Takeshita K; Morita J; Iwamoto S; Miyazaki A; Yoshida H
    Int J Urol; 2007 Jun; 14(6):532-8; discussion 538. PubMed ID: 17593099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.